Dayton Clinical Oncology Program | Wright-Patterson Medical Center

Research site

(Unclaimed)

Location

88 MPG 4881 Sugar Maple Drive, Wright-Patterson Air Force Base, Ohio, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Bevacizumab

Carboplatin

Cisplatin

Docetaxel

Gemcitabine Hydrochloride

Ibrutinib

Crizotinib

Doxorubicin Hydrochloride

Anastrozole

Parent organization

This site is a part of Dayton Clinical Oncology Program

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 82 total trials

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting

Hormone-resistant Prostate Cancer

Stage IV Prostate Cancer

Drug: prednisone

Drug: enzalutamide

S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting

Colorectal Neoplasms

Drug: eflornithine & sulindac placebo

Drug: Eflornithine placebo & sulindac placebo

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen depriva...

Active, not recruiting

Prostate Cancer

Drug: Bicalutamide

Drug: TAK-700

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab/rHuPH20

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy...

Active, not recruiting

Recurrent Primary Peritoneal Carcinoma

Ovarian Undifferentiated Carcinoma

Drug: Gemcitabine

Drug: Cediranib Maleate